Avita Medical

259 articles about Avita Medical

• The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company

  2/23/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to market the RECELL® System in Japan.

• AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference

  2/23/2022

  AVITA Medical, Inc. announced that Dr. Mike Perry, CEO, will present at the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 12:50 p.m. Eastern Standard Time.

• AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use

  2/17/2022

  AVITA Medical, Inc. announced that the United States Food and Drug Administration has reviewed and approved the premarket approval application supplement for RECELL® Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

• AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results

  2/15/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it plans to release its July 1, 2021 to December 31, 2021 financial results after the market closes on Monday, February 28, 2022.

• RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care SymposiumData presentations highlight broad clinical adoption of the RECELL® System for treatment of burn wounds

  1/24/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that six abstracts highlighting the clinical benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been accepted at the 44th Annual John A. Boswick Burn & Wound Care Symposium.

• AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021

  1/10/2022

  AVITA Medical, Inc. announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2021.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin CellsData show promise for skin rejuvenation and treatment of epidermolysis bullosa

  1/6/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), today announced that preclinical data successfully established proof of concept in two key areas of cell-based gene therapy – skin rejuvenation and epidermolysis bullosa.

• AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue ReconstructionTopline data expected in second half of 2022

  1/6/2022

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that it has completed enrollment into its pivotal trial for the use of the RECELL® System for soft-tissue reconstruction.

• 

  Clinical Catch-Up: December 11-17

  12/20/2021

  It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.

• AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable VitiligoTopline data expected in second half of 2022

  12/15/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that it has completed enrollment into its pivotal trial for the use of the RECELL® System for repigmentation of stable vitiligo.

• AVITA Medical to Present at Upcoming Investor Conferences - Nov 16, 2021

  11/16/2021

  AVITA Medical, Inc. announced that its management will present at the following upcoming investor conferences.

• AVITA Medical Reports First Fiscal Quarter 2022 Financial Results

  11/8/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its first fiscal quarter ended September 30, 2021.

• Regional Burn Conferences Feature 12 RECELL® System Data Presentations by Prominent Burn SurgeonsData underscores broad clinical utility and health economic benefits of the RECELL® System

  10/28/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that 12 RECELL® System data presentations will be shared at the upcoming Southern and Northeast Regional Burn Conferences.

• AVITA Medical to Announce Fiscal First Quarter 2022 Financial Results

  10/25/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal first quarter 2022 financial results after the market closes on Monday, November 8, 2021.

• AVITA Medical to Present at the 2021 Cantor Virtual Global Healthcare Conference

  9/13/2021

  AVITA Medical, Inc. announced today that its management will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 4:00 p.m. Eastern Daylight Time

• AVITA Medical to Participate at the Lake Street 2021 BIG5 Conference

  8/31/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will participate at the Lake Street 2021 BIG5 Conference on Tuesday, September 14, 2021

• AVITA Medical Reports Fourth Quarter and Fiscal Year 2021 Financial Results

  8/26/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), today reported financial results for its fourth quarter of fiscal year 2021, ended June 30, 2021.

• FDA Approves IDE Amendment to a Single-Arm Design for AVITA Medical’s Pivotal Study of the RECELL® System for Vitiligo Treatment

  8/16/2021

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s request to amend its pivotal clinical trial evaluating the safety and effectiveness of the RECELL® System for the repigmentation of stable vitiligo lesions to a streamlined single-arm trial design.

• AVITA Medical to Announce Fiscal Fourth Quarter 2021 Financial Results

  8/12/2021

  AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced it plans to release its fiscal fourth quarter 2021 financial results after the market closes on Thursday, August 26, 2021.